Treatment of the Special Patient with Schizophrenia

Overview

Journal Dialogues Clin Neurosci

Specialty Neurology

Date 2011 Oct 29

PMID 22034474

Citations 1

Authors

R R Conley

D L Kelly

Affiliations

Soon will be listed here.

Abstract

Special patient populations with schizophrenia have received little attention. These populations include adolescents, the elderly, substance abusers, and patients who are considered treatment-resistant. Interest in these populations is rapidly growing, especially with regard to their treatment with second-generation antipsychotics. This article describes the treatment of special patient populations and summarizes the research that has been done in this field.

Citing Articles

Potential molecular and cellular mechanism of psychotropic drugs.

Seo M, Scarr E, Lai C, Dean B Clin Psychopharmacol Neurosci. 2014; 12(2):94-110.

PMID: 25191500 PMC: 4153869. DOI: 10.9758/cpn.2014.12.2.94.

References

Dixon L, Dibietz E, Myers P, Conley R, Medoff D, Lehman A . Comparison of DSM-III-R diagnoses and a brief interview for substance use among state hospital patients. Hosp Community Psychiatry. 1993; 44(8):748-52. DOI: 10.1176/ps.44.8.748. View

Davis J, Casper R . Antipsychotic drugs: clinical pharmacology and therapeutic use. Drugs. 1977; 14(4):260-82. DOI: 10.2165/00003495-197714040-00002. View

Marder S, Meibach R . Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994; 151(6):825-35. DOI: 10.1176/ajp.151.6.825. View

Kales H, DeQuardo J, Tandon R . Combined electroconvulsive therapy and clozapine in treatment-resistant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 1999; 23(3):547-56. DOI: 10.1016/s0278-5846(99)00015-9. View

Conley R, Tamminga C, Kelly D, Richardson C . Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. Biol Psychiatry. 1999; 46(1):73-7. DOI: 10.1016/s0006-3223(99)00029-3. View

Christison G, Kirch D, Wyatt R . When symptoms persist: choosing among alternative somatic treatments for schizophrenia. Schizophr Bull. 1991; 17(2):217-45. DOI: 10.1093/schbul/17.2.217. View

Misra L, Kofoed L . Risperidone treatment of methamphetamine psychosis. Am J Psychiatry. 1997; 154(8):1170. DOI: 10.1176/ajp.154.8.1170a. View

Flynn S, MacEwan G, Altman S, Kopala L, Fredrikson D, Smith G . An open comparison of clozapine and risperidone in treatment-resistant schizophrenia. Pharmacopsychiatry. 1998; 31(1):25-9. DOI: 10.1055/s-2007-979291. View

Brenner H, Dencker S, Goldstein M, Hubbard J, Keegan D, Kruger G . Defining treatment refractoriness in schizophrenia. Schizophr Bull. 1990; 16(4):551-61. DOI: 10.1093/schbul/16.4.551. View

10.

Conley R, Tamminga C, Bartko J, Richardson C, Peszke M, Lingle J . Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry. 1998; 155(7):914-20. DOI: 10.1176/ajp.155.7.914. View

11.

Wragg R, Jeste D . Overview of depression and psychosis in Alzheimer's disease. Am J Psychiatry. 1989; 146(5):577-87. DOI: 10.1176/ajp.146.5.577. View

12.

VAN KAMMEN D, Schooler N . Are biochemical markers for treatment-resistant schizophrenia state dependent or traits?. Clin Neuropharmacol. 1990; 13 Suppl 1:S16-28. DOI: 10.1097/00002826-199001001-00002. View

13.

Potenza M, Holmes J, Kanes S, McDougle C . Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol. 1999; 19(1):37-44. DOI: 10.1097/00004714-199902000-00008. View

14.

. The epidemiology of mental disorders: results from the Epidemiologic Catchment Area Study (ECA). Psychopharmacol Bull. 1982; 18(3):222-5. View

15.

Haywood T, Kravitz H, Grossman L, Cavanaugh Jr J, Davis J, Lewis D . Predicting the "revolving door" phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. Am J Psychiatry. 1995; 152(6):856-61. DOI: 10.1176/ajp.152.6.856. View

16.

Birmaher B, Baker R, Kapur S, Quintana H, Ganguli R . Clozapine for the treatment of adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry. 1992; 31(1):160-4. DOI: 10.1097/00004583-199201000-00024. View

17.

Wolkowitz O, Turetsky N, Reus V, Hargreaves W . Benzodiazepine augmentation of neuroleptics in treatment-resistant schizophrenia. Psychopharmacol Bull. 1992; 28(3):291-5. View

18.

Jeste D, Caligiuri M, Paulsen J, Heaton R, Lacro J, Harris M . Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry. 1995; 52(9):756-65. DOI: 10.1001/archpsyc.1995.03950210050010. View

19.

Baldessarini R, Cohen B, Teicher M . Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry. 1988; 45(1):79-91. DOI: 10.1001/archpsyc.1988.01800250095013. View

20.

Soyka M, Wegner U, Moeller H . Risperidone in treatment-refractory chronic alcohol hallucinosis. Pharmacopsychiatry. 1997; 30(4):135-6. DOI: 10.1055/s-2007-979500. View